This series of phase 3, randomised, double-blind, placebo-controlled clinical trials involved more than 25,000 individuals with overweight or obesity and has extensively demonstrated the efficacy of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss [13, 38,39,40,41,42,43,44,45,46]
You deserve only the best
Enter the desired dose you want to inject
Implications for marketers: Interest in GLP-1s is highest among consumers diagnosed as overweight or obese, but weight loss isnt always what motivates people to use GLP-1s
Regular check-ins allow us to adjust your plan based on how your body responds